TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Rand, Doubleblind, Activecontrolled, Parallel-grp,Singledummy, Multicenter,12 wk Study to Assess the Effic.&Safety of Symbicort pMDI 2x160/4.5mcg QD Compared to Symb. pMDI 2x80/4.5mcg QD, Symb. pMDI 2x80/4.5mcg Bid and to Budesonide pMDI 2x160 Mcg QD in Asthmatic Sub's12yrs and Over
Brief Summary: The purpose of this study is to determine whether treatment with Symbicort for 12 weeks will improve lung function and symptoms of adults and adolescents with asthma.


Options:
A: Arm Label: Fluticasone Furoate/Vilanterol 100/25 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler, Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler | Arm Label: Fluticasone Propionate/Salmeterol 250/50 mcg; Type: EXPERIMENTAL; Interventions: Drug: Placebo inhalation powders via ELLIPTA inhaler, Drug: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler | Arm Label: Fluticasone Propionate 250 mcg; Type: EXPERIMENTAL; Interventions: Drug: Placebo inhalation powders via ELLIPTA inhaler, Drug: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler; Assigned to Arm(s): Fluticasone Furoate/Vilanterol 100/25 mcg | Intervention Type: DRUG; Name: Placebo inhalation powders via ELLIPTA inhaler; Assigned to Arm(s): Fluticasone Propionate 250 mcg, Fluticasone Propionate/Salmeterol 250/50 mcg | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler; Assigned to Arm(s): Fluticasone Propionate/Salmeterol 250/50 mcg | Intervention Type: DRUG; Name: Placebo inhalation powder via ACCUHALER/DISKUS inhaler; Assigned to Arm(s): Fluticasone Furoate/Vilanterol 100/25 mcg | Intervention Type: DRUG; Name: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler; Assigned to Arm(s): Fluticasone Propionate 250 mcg
B: Arm Label: FF/VI 200/25mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: GW685698/GW642444 | Arm Label: Fluticasone propionate 500mcg twice daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: CCI18781 | Intervention Type: DRUG; Name: GW685698/GW642444; Assigned to Arm(s): FF/VI 200/25mcg once daily | Intervention Type: DRUG; Name: CCI18781; Assigned to Arm(s): Fluticasone propionate 500mcg twice daily
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1
D: Arm Label: tiotropium 5mcg/day; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 5mcg/day | Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium 5mcg/day; Assigned to Arm(s): tiotropium 5mcg/day | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Rand, Doubleblind, Activecontrolled, Parallel-grp,Singledummy, Multicenter,12 wk Study to Assess the Effic.&Safety of Symbicort pMDI 2x160/4.5mcg QD Compared to Symb. pMDI 2x80/4.5mcg QD, Symb. pMDI 2x80/4.5mcg Bid and to Budesonide pMDI 2x160 Mcg QD in Asthmatic Sub's12yrs and Over
Brief Summary: The purpose of this study is to determine whether treatment with Symbicort for 12 weeks will improve lung function and symptoms of adults and adolescents with asthma.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1
B: Arm Label: Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 320/28.8/9.6 μg | Arm Label: BGF MDI 320/14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 320/14.4/9.6 μg | Arm Label: Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: BFF MDI 320/9.6 μg | Arm Label: Symbicort®; Type: ACTIVE_COMPARATOR; Interventions: Drug: BFF pMDI 320/9 μg | Intervention Type: DRUG; Name: BGF MDI 320/28.8/9.6 μg; Assigned to Arm(s): Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg | Intervention Type: DRUG; Name: BGF MDI 320/14.4/9.6 μg; Assigned to Arm(s): BGF MDI 320/14.4/9.6 μg | Intervention Type: DRUG; Name: BFF MDI 320/9.6 μg; Assigned to Arm(s): Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg | Intervention Type: DRUG; Name: BFF pMDI 320/9 μg; Assigned to Arm(s): Symbicort®
C: Arm Label: Fluticasone Furoate (FF); Type: ACTIVE_COMPARATOR; Interventions: Drug: FF | Arm Label: Fluticasone Furoate /Vilanterol (VI); Type: ACTIVE_COMPARATOR; Interventions: Drug: FF/VI | Arm Label: Fluticasone Furoate/GSK573719; Type: EXPERIMENTAL; Interventions: Drug: FF/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF/GSK573719; Assigned to Arm(s): Fluticasone Furoate/GSK573719 | Intervention Type: DRUG; Name: FF; Assigned to Arm(s): Fluticasone Furoate (FF) | Intervention Type: DRUG; Name: FF/VI; Assigned to Arm(s): Fluticasone Furoate /Vilanterol (VI)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: FOSTER | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Seretide | Intervention Type: DRUG; Name: FOSTER; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Seretide; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two Stage Randomized, Open-Label, Parallel Group, Phase III, Multicenter, 7 Month Study to Assess the Efficacy & Safety of SYMBICORT pMDI Adminstered Either as Fixed or as an Adjustable Regimen Versus a Fixed Regimen of Advair in Subjects 12 Yrs of Age and Older With Asthma.
Brief Summary: The purpose of this study is to determine whether Symbicort compared with Advair, will be more effective in controlling asthma in adults and adolescents.


Options:
A: Arm Label: ADVAIR 100/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 100/50mcg | Arm Label: ADVAIR 250/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 250/50mcg | Arm Label: FLOVENT 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 100mcg | Arm Label: FLOVENT 250mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 250mcg | Intervention Type: DRUG; Name: ADVAIR 100/50mcg; Assigned to Arm(s): ADVAIR 100/50mcg | Intervention Type: DRUG; Name: ADVAIR 250/50mcg; Assigned to Arm(s): ADVAIR 250/50mcg | Intervention Type: DRUG; Name: FLOVENT 100mcg; Assigned to Arm(s): FLOVENT 100mcg | Intervention Type: DRUG; Name: FLOVENT 250mcg; Assigned to Arm(s): FLOVENT 250mcg
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol (Advair) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: fluticasone/salmeterol (Advair); Assigned to Arm(s): 2
C: Arm Label: ADVAIR 100/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 100/50mcg | Arm Label: ADVAIR 250/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 250/50mcg | Arm Label: ADVAIR 500/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 500/50mcg | Arm Label: FLOVENT 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 100mcg | Arm Label: FLOVENT 250mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 250mcg | Arm Label: FLOVENT 500mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 500mcg | Intervention Type: DRUG; Name: ADVAIR 100/50mcg; Assigned to Arm(s): ADVAIR 100/50mcg | Intervention Type: DRUG; Name: ADVAIR 250/50mcg; Assigned to Arm(s): ADVAIR 250/50mcg | Intervention Type: DRUG; Name: ADVAIR 500/50mcg; Assigned to Arm(s): ADVAIR 500/50mcg | Intervention Type: DRUG; Name: FLOVENT 100mcg; Assigned to Arm(s): FLOVENT 100mcg | Intervention Type: DRUG; Name: FLOVENT 250mcg; Assigned to Arm(s): FLOVENT 250mcg | Intervention Type: DRUG; Name: FLOVENT 500mcg; Assigned to Arm(s): FLOVENT 500mcg
D: Intervention Type: DRUG; Name: beclomethasone dipropionate plus formoterol fumarate combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone propionate plus salmeterol xinafoate combination; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two Stage Randomized, Open-Label, Parallel Group, Phase III, Multicenter, 7 Month Study to Assess the Efficacy & Safety of SYMBICORT pMDI Adminstered Either as Fixed or as an Adjustable Regimen Versus a Fixed Regimen of Advair in Subjects 12 Yrs of Age and Older With Asthma.
Brief Summary: The purpose of this study is to determine whether Symbicort compared with Advair, will be more effective in controlling asthma in adults and adolescents.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol (Advair) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: fluticasone/salmeterol (Advair); Assigned to Arm(s): 2
B: Arm Label: Daily ICS + Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Daily ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albuterol sulfate | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS + Rescue ICS, Rescue ICS | Intervention Type: DRUG; Name: Albuterol sulfate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS, Placebo, Rescue ICS
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide, Drug: terbutaline | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: terbutaline | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide/formoterol | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: terbutaline; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: budesonide/formoterol; Assigned to Arm(s): C
D: Arm Label: Beclometasone/formoterol (100/6 µg); Type: EXPERIMENTAL; Interventions: Drug: beclometasone /formoterol | Arm Label: salbutamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ventolin | Intervention Type: DRUG; Name: Ventolin; Assigned to Arm(s): salbutamol | Intervention Type: DRUG; Name: beclometasone /formoterol; Assigned to Arm(s): Beclometasone/formoterol (100/6 µg)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two Stage Randomized, Open-Label, Parallel Group, Phase III, Multicenter, 7 Month Study to Assess the Efficacy & Safety of SYMBICORT pMDI Adminstered Either as Fixed or as an Adjustable Regimen Versus a Fixed Regimen of Advair in Subjects 12 Yrs of Age and Older With Asthma.
Brief Summary: The purpose of this study is to determine whether Symbicort compared with Advair, will be more effective in controlling asthma in adults and adolescents.


Options:
A: Arm Label: tiotropium 5 mcg; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 5 mcg | Arm Label: tiotropium 2.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 2.5 mcg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: tiotropium 2.5 mcg; Assigned to Arm(s): tiotropium 2.5 mcg | Intervention Type: DRUG; Name: tiotropium 5 mcg; Assigned to Arm(s): tiotropium 5 mcg
B: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder | Arm Label: Fluticasone Furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaltion Powder | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Placebo Inhaltion Powder; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol (Advair) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: fluticasone/salmeterol (Advair); Assigned to Arm(s): 2
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol/fluticasone propionate and fluticasone propionate | Intervention Type: DRUG; Name: Salmeterol/fluticasone propionate and fluticasone propionate; Assigned to Arm(s): Arm 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two Stage Randomized, Open-Label, Parallel Group, Phase III, Multicenter, 7 Month Study to Assess the Efficacy & Safety of SYMBICORT pMDI Adminstered Either as Fixed or as an Adjustable Regimen Versus a Fixed Regimen of Advair in Subjects 12 Yrs of Age and Older With Asthma.
Brief Summary: The purpose of this study is to determine whether Symbicort compared with Advair, will be more effective in controlling asthma in adults and adolescents.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol (Advair) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: fluticasone/salmeterol (Advair); Assigned to Arm(s): 2
B: Arm Label: Flutiform 250/10 micrograms; Type: EXPERIMENTAL; Interventions: Drug: Flutiform 250/10 micrograms | Arm Label: Flutiform 50/5 micrograms; Type: EXPERIMENTAL; Interventions: Drug: Flutiform 50/5 micrograms | Arm Label: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms | Arm Label: Flixotide pMDI 250 micrograms; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flixotide pMDI 250 micrograms | Intervention Type: DRUG; Name: Flutiform 250/10 micrograms; Assigned to Arm(s): Flutiform 250/10 micrograms | Intervention Type: DRUG; Name: Flutiform 50/5 micrograms; Assigned to Arm(s): Flutiform 50/5 micrograms | Intervention Type: DRUG; Name: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms; Assigned to Arm(s): Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms | Intervention Type: DRUG; Name: Flixotide pMDI 250 micrograms; Assigned to Arm(s): Flixotide pMDI 250 micrograms
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol/fluticasone propionate or formoterol/budesonide | Intervention Type: DRUG; Name: Salmeterol/fluticasone propionate or formoterol/budesonide; Assigned to Arm(s): Arm 1
D: Intervention Type: DRUG; Name: Budesonide/formoterol Turbuhaler; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol/fluticasone Diskus; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors
Brief Summary: Based on the investigators clinical experience in patients with chronic disease (Hui, Hui, and Johnston, 2006; Hays et al 2005), a review of the literature (Johnston, Xiao and Hui 2007), and inspired by Vickers and colleagues (PMID: 15117996), the investigators carry out a pilot study that investigates if acupuncture combined with patient education will relieve fatigue in patients who have completed primary treatment for breast cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and relaxation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and physical activity | Arm Label: 4; Type: NO_INTERVENTION; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: CBT and relaxation; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: CBT and physical activity; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 4
B: Arm Label: Acupuncture & educ; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Acupuncture and patient education | Arm Label: 2. Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Acupuncture and patient education; Assigned to Arm(s): Acupuncture & educ
C: Arm Label: Physical activity intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): Physical activity intervention
D: Arm Label: Group (GRP) phone counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Group phone counseling | Arm Label: Mail-based Comparison Condition; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Newsletter | Intervention Type: BEHAVIORAL; Name: Group phone counseling; Assigned to Arm(s): Group (GRP) phone counseling | Intervention Type: BEHAVIORAL; Name: Newsletter; Assigned to Arm(s): Mail-based Comparison Condition

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors
Brief Summary: Based on the investigators clinical experience in patients with chronic disease (Hui, Hui, and Johnston, 2006; Hays et al 2005), a review of the literature (Johnston, Xiao and Hui 2007), and inspired by Vickers and colleagues (PMID: 15117996), the investigators carry out a pilot study that investigates if acupuncture combined with patient education will relieve fatigue in patients who have completed primary treatment for breast cancer.


Options:
A: Arm Label: Resistance training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive resistance training | Arm Label: Relaxation training; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised progressive muscle relaxation training (Jacobson method) | Intervention Type: OTHER; Name: Supervised progressive resistance training; Assigned to Arm(s): Resistance training | Intervention Type: OTHER; Name: Supervised progressive muscle relaxation training (Jacobson method); Assigned to Arm(s): Relaxation training
B: Arm Label: Acupuncture & educ; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Acupuncture and patient education | Arm Label: 2. Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Acupuncture and patient education; Assigned to Arm(s): Acupuncture & educ
C: Intervention Type: PROCEDURE; Name: Memory Training; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors
Brief Summary: To determine whether a combination of corticosteroids and azathioprine can achieve a higher remission rate and a lower subsequent relapse rate in patients with newly-diagnosed microscopic polyangiitis, polyarteritis nodosa or eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome) with no poor prognosis factor (FFS=0), and without significantly increasing the rate of adverse events, as compared to corticosteroids alone. The study hypothesis is a reduction of the absolute risk of treatment failure or relapse within the first 24 months following initiation of therapy of least 25%.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Plasma exchange | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous methyl prednisolone, Drug: Methyl prednisolone | Intervention Type: PROCEDURE; Name: Plasma exchange; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Intravenous methyl prednisolone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methyl prednisolone; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: corticosteroid and azathioprine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: corticosteroid and placebo | Intervention Type: DRUG; Name: corticosteroid and azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: corticosteroid and placebo; Assigned to Arm(s): 2
C: Arm Label: Valaciclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valaciclovir | Arm Label: No additional treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Valaciclovir; Assigned to Arm(s): Valaciclovir
D: Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Prednisone (and methylprednisolone); Assigned to Arm(s): N/A

Answer: B